An interview with Dr. Michael J. Morris from Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine on the ASCO clinical practice guideline which addresses abiraterone or docetaxel with androgen-deprivation therapy (ADT) for metastatic prostate cancer that has not been treated (or has been minimally treated) with testosterone-lowering agents. Read the full guideline at www.asco.org/genitourinary-cancer-guidelines